GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (NAS:RVNC) » Definitions » Market Cap

Revance Therapeutics (Revance Therapeutics) Market Cap : $395.0 Mil (As of May. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Revance Therapeutics's share price for the quarter that ended in Dec. 2023 was $8.79. Revance Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 88.0 Mil. Therefore, Revance Therapeutics's market cap for the quarter that ended in Dec. 2023 was $773.2 Mil.

Revance Therapeutics's quarterly market cap declined from Jun. 2023 ($2,226.0 Mil) to Sep. 2023 ($1,007.2 Mil) and declined from Sep. 2023 ($1,007.2 Mil) to Dec. 2023 ($773.2 Mil).

Revance Therapeutics's annual market cap increased from Dec. 2021 ($1,168.3 Mil) to Dec. 2022 ($1,520.8 Mil) but then declined from Dec. 2022 ($1,520.8 Mil) to Dec. 2023 ($773.2 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Revance Therapeutics's Enterprise Value for Today is $600.7 Mil.


Revance Therapeutics Market Cap Historical Data

The historical data trend for Revance Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics Market Cap Chart

Revance Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 850.04 1,960.52 1,168.25 1,520.84 773.19

Revance Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,520.84 2,706.19 2,226.01 1,007.22 773.19

Competitive Comparison of Revance Therapeutics's Market Cap

For the Biotechnology subindustry, Revance Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revance Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's Market Cap falls into.



Revance Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Revance Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$8.79*87.9628
=$773.2

Revance Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$8.79*87.9628
=$773.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revance Therapeutics  (NAS:RVNC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Revance Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Revance Therapeutics (Revance Therapeutics) Business Description

Traded in Other Exchanges
Address
1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Executives
Dwight Moxie officer: SVP, GC & Secretary 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tobin Schilke officer: Chief Financial Officer 7000 SHORELINE COURT, #371, SOUTH SAN FRANCISCO CA 94080
Carey Oconnor Kolaja director C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, SUITE 1001, NASHVILLE TN 37203
Dustin S Sjuts officer: President 7555 GATEWAY BLVD, NEWARK CA 94560
Vlad Coric director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Aubrey Rankin director C/O REVANCE THERAPEUTICS, INC, 7555 GATEWAY BLVD, NEWARK CA 94560
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Jill Beraud director C/O LEVI STRAUSS & CO., 1155 BATTERY STREET, SAN FRANCISCO CA 94111
L Daniel Browne director, officer: CEO and President 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Cyril Allouche officer: Principal Financial Officer 7555 GATEWAY BLVD., NEWARK CA 94560
Lauren P Silvernail officer: CFO, Seretary & EVP Corp Dev. 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Caryn Gordon Mcdowell officer: SVP, GC & Secretary 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080